A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
Status:
Withdrawn
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to assess the efficacy of two dose strengths of
varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in
symptomatically stable outpatient schizophrenic subjects who are receiving treatment with
atypical antipsychotic medications.
A secondary objective is to evaluate the safety and tolerability of two doses of varenicline
in symptomatically stable schizophrenic subjects who are receiving treatment with atypical
antipsychotic medications.